NASDAQ:UPB Upstream Bio Q2 2026 Earnings Report $5.30 -0.06 (-1.12%) Closing price 04:00 PM EasternExtended Trading$5.30 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Upstream Bio EPS ResultsActual EPS-$0.73Consensus EPS -$0.74Beat/MissBeat by +$0.01One Year Ago EPSN/AUpstream Bio Revenue ResultsActual Revenue$0.77 millionExpected Revenue$0.56 millionBeat/MissBeat by +$212.00 thousandYoY Revenue GrowthN/AUpstream Bio Announcement DetailsQuarterQ2 2026Date8/11/2026TimeBefore Market OpensConference Call DateTuesday, August 11, 2026Conference Call Time7:00AM ETUpcoming EarningsUpstream Bio's Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Upstream Bio Earnings HeadlinesHead to Head Analysis: Upstream Bio (NASDAQ:UPB) & Aclaris Therapeutics (NASDAQ:ACRS)September 28 at 8:45 AM | americanbankingnews.comUpstream Bio Reports Phase 2 VALIANT Trial Results Showing Verekitug Reduced Severe Asthma Exacerbations by 56% with Quarterly DosingSeptember 8, 2026 | quiverquant.comQFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.September 28 at 1:00 AM | Stansberry Research (Ad)Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026September 8, 2026 | globenewswire.comAnalysts Are Bullish on These NA Stocks: Upstream Bio, Inc. (UPB), Fervo Energy Company Class A (FRVO)September 2, 2026 | theglobeandmail.comUpstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027September 1, 2026 | finance.yahoo.comSee More Upstream Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Upstream Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Upstream Bio and other key companies, straight to your email. Email Address About Upstream BioUpstream Bio (NASDAQ:UPB) is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-mediated diseases. The company’s research is centered on targeting biological pathways involved in chronic inflammation, with the goal of addressing conditions that may not be adequately controlled by existing therapies. Upstream Bio’s lead product candidate is verekitug, a monoclonal antibody designed to block thymic stromal lymphopoietin (TSLP), an epithelial-cell-derived cytokine that plays a role in initiating and sustaining allergic and inflammatory responses. The company is evaluating verekitug in respiratory and immunologic conditions, including severe asthma and chronic rhinosinusitis with nasal polyps. Upstream Bio conducts clinical development activities in collaboration with research institutions and healthcare providers, with its programs focused primarily on patients in major global pharmaceutical and biotechnology markets. The company is headquartered in the United States and is advancing its pipeline through clinical-stage research rather than commercial product sales.View Upstream Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum2 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindFertilizer Prices Keep Climbing: 3 Stocks Still Trading at a Discount Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
